CMV infection · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to lower CMV infection compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Wound complications · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher adverse wound outcomes: all complications compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
All malignancies · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in all malignancies compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Number needing to change treatment · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher number needing to change treatment compared with antimetabolites: primary outcomes (moderate certainty).
1 finding from 1 review
Outcomes (up to 2 years for secondary outcomes) · primary immunosuppression in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New onset of diabetes · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher new‐onset diabetes mellitus compared with antimetabolites: secondary outcomes (moderate certainty).
1 finding from 1 review
BK virus infection · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) leads to lower BK virus infection compared with antimetabolites: secondary outcomes (high certainty).
1 finding from 1 review
GFR · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher hypercholesterolaemia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Hypertriglyceridaemia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) probably leads to higher hypertriglyceridaemia compared with antimetabolites: secondary outcomes (moderate certainty).
1 finding from 1 review
Leucopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to lower leucopenia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with antimetabolites: secondary outcomes (low certainty).
1 finding from 1 review
Visual acuity · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
2 findings from 1 review
Adherence · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Ocular alignment (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 24 months, or cessation of treatment) and by the proportions of participants who developed strabismus, showed chang... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Stereo acuity (different measures and time points reported in the included studies) Assessed at different time points (17 weeks, 6 months, 2 years, or at cessation of treatment) and using different measures (TNO stereo test, Titmus fly test, Rando... · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Quality of life (different measures and time points reported in the included studies) Assessed at different time points (17 weeks or 6 months) by patient preference or the Amblyopia Treatment Index questionnaire. · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Adverse events (reported occurrence of: mild reduction in the visual acuity of the sound eye not requiring treatment; light sensitivity; skin, lid, or conjunctival irritation) Assessed at different time points (17 weeks or 2 years). · Participants of any age with either unilateral strabismic, anisometropic, or mixed (strabismic‐refractive) amblyopia; deprivation…
1 finding from 1 review
Clinical pregnancy · assisted reproductive technology
It is very uncertain whether piroxicam changes clinical pregnancy compared with indomethacin (very low certainty).
1 finding from 1 review
Ectopic pregnancy · assisted reproductive technology
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found